ID   HIF1N_HUMAN             Reviewed;         349 AA.
AC   Q9NWT6; D3DR69; Q5W147; Q969Q7; Q9NPV5;
DT   16-JUN-2003, integrated into UniProtKB/Swiss-Prot.
DT   16-JUN-2003, sequence version 2.
DT   15-MAR-2017, entry version 155.
DE   RecName: Full=Hypoxia-inducible factor 1-alpha inhibitor;
DE            EC=1.14.11.30;
DE            EC=1.14.11.n4;
DE   AltName: Full=Factor inhibiting HIF-1;
DE            Short=FIH-1;
DE   AltName: Full=Hypoxia-inducible factor asparagine hydroxylase;
GN   Name=HIF1AN; Synonyms=FIH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH HIF1A; VHL AND
RP   HISTONE DEACETYLASES.
RC   TISSUE=Brain;
RX   PubMed=11641274; DOI=10.1101/gad.924501;
RA   Mahon P.C., Hirota K., Semenza G.L.;
RT   "FIH-1: a novel protein that interacts with HIF-1alpha and VHL to
RT   mediate repression of HIF-1 transcriptional activity.";
RL   Genes Dev. 15:2675-2686(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Signet-ring cell carcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-41.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 89-349.
RC   TISSUE=Melanoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   CATALYTIC ACTIVITY, FUNCTION, AND MUTAGENESIS OF HIS-199 AND ASP-201.
RX   PubMed=12080085; DOI=10.1101/gad.991402;
RA   Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L.,
RA   Bruick R.K.;
RT   "FIH-1 is an asparaginyl hydroxylase enzyme that regulates the
RT   transcriptional activity of hypoxia-inducible factor.";
RL   Genes Dev. 16:1466-1471(2002).
RN   [8]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=12042299; DOI=10.1074/jbc.C200273200;
RA   Hewitson K.S., McNeill L.A., Riordan M.V., Tian Y.-M., Bullock A.N.,
RA   Welford R.W., Elkins J.M., Oldham N.J., Bhattacharya S., Gleadle J.M.,
RA   Ratcliffe P.J., Pugh C.W., Schofield C.J.;
RT   "Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to
RT   factor inhibiting HIF (FIH) and is related to the cupin structural
RT   family.";
RL   J. Biol. Chem. 277:26351-26355(2002).
RN   [9]
RP   DIMERIZATION, MASS SPECTROMETRY, AND MUTAGENESIS OF LEU-340 AND
RP   ILE-344.
RX   PubMed=15239670; DOI=10.1042/BJ20040735;
RA   Lancaster D.E., McNeill L.A., McDonough M.A., Aplin R.T.,
RA   Hewitson K.S., Pugh C.W., Ratcliffe P.J., Schofield C.J.;
RT   "Disruption of dimerization and substrate phosphorylation inhibit
RT   factor inhibiting hypoxia-inducible factor (FIH) activity.";
RL   Biochem. J. 383:429-437(2004).
RN   [10]
RP   CATALYTIC ACTIVITY, SUBUNIT, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=14701857; DOI=10.1074/jbc.M312254200;
RA   Koivunen P., Hirsila M., Gunzler V., Kivirikko K.I., Myllyharju J.;
RT   "Catalytic properties of the asparaginyl hydroxylase (FIH) in the
RT   oxygen sensing pathway are distinct from those of its prolyl 4-
RT   hydroxylases.";
RL   J. Biol. Chem. 279:9899-9904(2004).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=14734545; DOI=10.1074/jbc.M313614200;
RA   Linke S., Stojkoski C., Kewley R.J., Booker G.W., Whitelaw M.L.,
RA   Peet D.J.;
RT   "Substrate requirements of the oxygen-sensing asparaginyl hydroxylase
RT   factor-inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 279:14391-14397(2004).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH NFKB1 AND NFKBIA.
RX   PubMed=17003112; DOI=10.1073/pnas.0606877103;
RA   Cockman M.E., Lancaster D.E., Stolze I.P., Hewitson K.S.,
RA   McDonough M.A., Coleman M.L., Coles C.H., Yu X., Hay R.T., Ley S.C.,
RA   Pugh C.W., Oldham N.J., Masson N., Schofield C.J., Ratcliffe P.J.;
RT   "Posttranslational hydroxylation of ankyrin repeats in IkappaB
RT   proteins by the hypoxia-inducible factor (HIF) asparaginyl
RT   hydroxylase, factor inhibiting HIF (FIH).";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:14767-14772(2006).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18299578; DOI=10.1073/pnas.0711591105;
RA   Zheng X., Linke S., Dias J.M., Zheng X., Gradin K., Wallis T.P.,
RA   Hamilton B.R., Gustafsson M., Ruas J.L., Wilkins S., Bilton R.L.,
RA   Brismar K., Whitelaw M.L., Pereira T., Gorman J.J., Ericson J.,
RA   Peet D.J., Lendahl U., Poellinger L.;
RT   "Interaction with factor inhibiting HIF-1 defines an additional mode
RT   of cross-coupling between the Notch and hypoxia signaling pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3368-3373(2008).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH PPP1R12A.
RX   PubMed=19245366; DOI=10.1042/BJ20081905;
RA   Webb J.D., Muranyi A., Pugh C.W., Ratcliffe P.J., Coleman M.L.;
RT   "MYPT1, the targeting subunit of smooth-muscle myosin phosphatase, is
RT   a substrate for the asparaginyl hydroxylase factor inhibiting hypoxia-
RT   inducible factor (FIH).";
RL   Biochem. J. 420:327-333(2009).
RN   [16]
RP   INTERACTION WITH APBA3, AND SUBCELLULAR LOCATION.
RX   PubMed=19726677; DOI=10.1074/jbc.M109.019216;
RA   Sakamoto T., Seiki M.;
RT   "Mint3 enhances the activity of hypoxia-inducible factor-1 (HIF-1) in
RT   macrophages by suppressing the activity of factor inhibiting HIF-1.";
RL   J. Biol. Chem. 284:30350-30359(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   INTERACTION WITH UBE3A.
RX   PubMed=22645313; DOI=10.1128/MCB.00201-12;
RA   Martinez-Noel G., Galligan J.T., Sowa M.E., Arndt V., Overton T.M.,
RA   Harper J.W., Howley P.M.;
RT   "Identification and proteomic analysis of distinct UBE3A/E6AP protein
RT   complexes.";
RL   Mol. Cell. Biol. 32:3095-3106(2012).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH IRON AND
RP   2-OXOGLUTARATE, AND SUBUNIT.
RX   PubMed=12432100; DOI=10.1073/pnas.202614999;
RA   Dann C.E. III, Bruick R.K., Deisenhofer J.;
RT   "Structure of factor-inhibiting hypoxia-inducible factor 1: an
RT   asparaginyl hydroxylase involved in the hypoxic response pathway.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:15351-15356(2002).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) IN COMPLEX WITH 786-826 OF
RP   HIF1A; IRON; ZINC AND 2-OXOGLUTARATE.
RX   PubMed=12446723; DOI=10.1074/jbc.C200644200;
RA   Elkins J.M., Hewitson K.S., McNeill L.A., Seibel J.F.,
RA   Schlemminger I., Pugh C.W., Ratcliffe P.J., Schofield C.J.;
RT   "Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals
RT   mechanism of oxidative modification of HIF-1 alpha.";
RL   J. Biol. Chem. 278:1802-1806(2003).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS), AND SUBUNIT.
RX   PubMed=12482756; DOI=10.1074/jbc.M210385200;
RA   Lee C., Kim S.J., Jeong D.G., Lee S.M., Ryu S.E.;
RT   "Structure of human FIH-1 reveals a unique active site pocket and
RT   interaction sites for HIF-1 and von Hippel-Lindau.";
RL   J. Biol. Chem. 278:7558-7563(2003).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) IN COMPLEX WITH IRON AND
RP   INHIBITOR.
RX   PubMed=15913349; DOI=10.1021/ja050841b;
RA   McDonough M.A., McNeill L.A., Tilliet M., Papamicael C.A., Chen Q.Y.,
RA   Banerji B., Hewitson K.S., Schofield C.J.;
RT   "Selective inhibition of factor inhibiting hypoxia-inducible factor.";
RL   J. Am. Chem. Soc. 127:7680-7681(2005).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) IN COMPLEX WITH IRON; SUCCINATE
RP   AND FUMARATE.
RX   PubMed=17135241; DOI=10.1074/jbc.M608337200;
RA   Hewitson K.S., Lienard B.M., McDonough M.A., Clifton I.J., Butler D.,
RA   Soares A.S., Oldham N.J., McNeill L.A., Schofield C.J.;
RT   "Structural and mechanistic studies on the inhibition of the hypoxia-
RT   inducible transcription factor hydroxylases by tricarboxylic acid
RT   cycle intermediates.";
RL   J. Biol. Chem. 282:3293-3301(2007).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) IN COMPLEXES WITH 1930-1949 OR
RP   1997-2016 OF MOUSE NOTCH1; IRON AND 2-OXOGLUTARATE, FUNCTION, AND
RP   SUBUNIT.
RX   PubMed=17573339; DOI=10.1074/jbc.M704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by
RT   factor inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 11-349 OF MUTANTS ALA-201
RP   AND GLY-201 IN COMPLEXES WITH 786-826 OR 788-806 OF HIF1A; IRON OR
RP   ZINC AND 2-OXOGLUTARATE, AND MUTAGENESIS OF ASP-201; TRP-296 AND
RP   LEU-340.
RX   PubMed=18611856; DOI=10.1074/jbc.M804999200;
RA   Hewitson K.S., Holmes S.L., Ehrismann D., Hardy A.P., Chowdhury R.,
RA   Schofield C.J., McDonough M.A.;
RT   "Evidence that two enzyme-derived histidine ligands are sufficient for
RT   iron binding and catalysis by factor inhibiting HIF (FIH).";
RL   J. Biol. Chem. 283:25971-25978(2008).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.12 ANGSTROMS) IN COMPLEX WITH IRON AND
RP   2-OXOGLUTARATE ANALOGS.
RX   PubMed=20822901; DOI=10.1016/j.bmcl.2010.08.032;
RA   Conejo-Garcia A., McDonough M.A., Loenarz C., McNeill L.A.,
RA   Hewitson K.S., Ge W., Lienard B.M., Schofield C.J., Clifton I.J.;
RT   "Structural basis for binding of cyclic 2-oxoglutarate analogues to
RT   factor-inhibiting hypoxia-inducible factor.";
RL   Bioorg. Med. Chem. Lett. 20:6125-6128(2010).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.59 ANGSTROMS) OF 15-349 IN COMPLEX WITH IRON
RP   AND QUINOL FAMILY INHIBITORS.
RX   PubMed=20396966; DOI=10.1007/s10059-010-0058-3;
RA   Moon H., Han S., Park H., Choe J.;
RT   "Crystal structures of human FIH-1 in complex with quinol family
RT   inhibitors.";
RL   Mol. Cells 29:471-474(2010).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) IN COMPLEX WITH IRON AND
RP   INHIBITORS.
RX   PubMed=21460794; DOI=10.1038/embor.2011.43;
RA   Chowdhury R., Yeoh K.K., Tian Y.M., Hillringhaus L., Bagg E.A.,
RA   Rose N.R., Leung I.K., Li X.S., Woon E.C., Yang M., McDonough M.A.,
RA   King O.N., Clifton I.J., Klose R.J., Claridge T.D., Ratcliffe P.J.,
RA   Schofield C.J., Kawamura A.;
RT   "The oncometabolite 2-hydroxyglutarate inhibits histone lysine
RT   demethylases.";
RL   EMBO Rep. 12:463-469(2011).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) IN COMPLEX WITH IRON;
RP   2-OXOGLUTARATE AND 538-558 OF TNKS2, AND FUNCTION.
RX   PubMed=21251231; DOI=10.1111/j.1742-4658.2011.08022.x;
RA   Yang M., Chowdhury R., Ge W., Hamed R.B., McDonough M.A.,
RA   Claridge T.D., Kessler B.M., Cockman M.E., Ratcliffe P.J.,
RA   Schofield C.J.;
RT   "Factor-inhibiting hypoxia-inducible factor (FIH) catalyses the post-
RT   translational hydroxylation of histidinyl residues within ankyrin
RT   repeat domains.";
RL   FEBS J. 278:1086-1097(2011).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF MUTANT HIS-239 IN COMPLEX
RP   WITH ZINC; N-OXALYLGLYCINE AND PEPTIDE SUBSTRATE, FUNCTION,
RP   INTERACTION WITH ANK1, AND MUTAGENESIS OF ASP-201 AND GLN-239.
RX   PubMed=21177872; DOI=10.1074/jbc.M110.193540;
RA   Yang M., Ge W., Chowdhury R., Claridge T.D., Kramer H.B.,
RA   Schmierer B., McDonough M.A., Gong L., Kessler B.M., Ratcliffe P.J.,
RA   Coleman M.L., Schofield C.J.;
RT   "Asparagine and aspartate hydroxylation of the cytoskeletal ankyrin
RT   family is catalyzed by factor-inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 286:7648-7660(2011).
CC   -!- FUNCTION: Hydroxylates HIF-1 alpha at 'Asp-803' in the C-terminal
CC       transactivation domain (CAD). Functions as an oxygen sensor and,
CC       under normoxic conditions, the hydroxylation prevents interaction
CC       of HIF-1 with transcriptional coactivators including Cbp/p300-
CC       interacting transactivator. Involved in transcriptional repression
CC       through interaction with HIF1A, VHL and histone deacetylases.
CC       Hydroxylates specific Asn residues within ankyrin repeat domains
CC       (ARD) of NFKB1, NFKBIA, NOTCH1, ASB4, PPP1R12A and several other
CC       ARD-containing proteins. Also hydroxylates Asp and His residues
CC       within ARDs of ANK1 and TNKS2, respectively. Negatively regulates
CC       NOTCH1 activity, accelerating myogenic differentiation. Positively
CC       regulates ASB4 activity, promoting vascular differentiation.
CC       {ECO:0000269|PubMed:12042299, ECO:0000269|PubMed:12080085,
CC       ECO:0000269|PubMed:17003112, ECO:0000269|PubMed:17573339,
CC       ECO:0000269|PubMed:18299578, ECO:0000269|PubMed:19245366,
CC       ECO:0000269|PubMed:21177872, ECO:0000269|PubMed:21251231}.
CC   -!- CATALYTIC ACTIVITY: Hypoxia-inducible factor-L-asparagine + 2-
CC       oxoglutarate + O(2) = hypoxia-inducible factor-(3S)-3-hydroxy-L-
CC       asparagine + succinate + CO(2).
CC   -!- CATALYTIC ACTIVITY: Ankyrin-repeat-L-histidine + 2-oxoglutarate +
CC       O(2) = ankyrin-repeat-(3S)-3-hydroxy-L-histidine + succinate +
CC       CO(2).
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:12432100,
CC         ECO:0000269|PubMed:12446723, ECO:0000269|PubMed:15913349,
CC         ECO:0000269|PubMed:17135241, ECO:0000269|PubMed:20396966,
CC         ECO:0000269|PubMed:20822901, ECO:0000269|PubMed:21251231,
CC         ECO:0000269|PubMed:21460794};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=100 uM for HIF1A (788-822) peptide
CC         {ECO:0000269|PubMed:14701857};
CC         KM=160 uM for HIF2A (832-866) peptide
CC         {ECO:0000269|PubMed:14701857};
CC         KM=0.5 uM for Fe(2+) {ECO:0000269|PubMed:14701857};
CC         KM=25 uM for 2-oxoglutarate {ECO:0000269|PubMed:14701857};
CC         KM=260 uM for ascorbate {ECO:0000269|PubMed:14701857};
CC         KM=90 uM for O(2) {ECO:0000269|PubMed:14701857};
CC         Note=The kinetic constants are determined for the recombinant
CC         FLAG-His-tagged protein.;
CC   -!- SUBUNIT: Homodimer; homodimerization is essential for catalytic
CC       activity. Interacts with VHL and HIF1A. Part of a complex with
CC       VHL, HIF1A and HDAC1 or HDAC2 or HDAC3. Interacts with NFKB1 and
CC       NFKBIA. Interacts with NOTCH1, NOTCH2 and NOTCH3 but not with
CC       NOTCH4. Interacts with APBA3; binding inhibits HIF1AN binding to
CC       HIF1A. Interacts with TNKS2. Interacts with PPP1R12A. Interacts
CC       with ASB4 (By similarity). Interacts with UBE3A. Interacts with
CC       ANKS3 (By similarity). {ECO:0000250|UniProtKB:Q8BLR9,
CC       ECO:0000269|PubMed:11641274, ECO:0000269|PubMed:12432100,
CC       ECO:0000269|PubMed:12446723, ECO:0000269|PubMed:12482756,
CC       ECO:0000269|PubMed:14701857, ECO:0000269|PubMed:15913349,
CC       ECO:0000269|PubMed:17003112, ECO:0000269|PubMed:17135241,
CC       ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:19245366,
CC       ECO:0000269|PubMed:19726677, ECO:0000269|PubMed:20396966,
CC       ECO:0000269|PubMed:20822901, ECO:0000269|PubMed:21177872,
CC       ECO:0000269|PubMed:21251231, ECO:0000269|PubMed:21460794,
CC       ECO:0000269|PubMed:22645313}.
CC   -!- INTERACTION:
CC       Q96DX5:ASB9; NbExp=3; IntAct=EBI-745632, EBI-745641;
CC       Q16665:HIF1A; NbExp=6; IntAct=EBI-745632, EBI-447269;
CC       Q96FW1:OTUB1; NbExp=4; IntAct=EBI-745632, EBI-1058491;
CC       P57078:RIPK4; NbExp=4; IntAct=EBI-745632, EBI-4422308;
CC       O95271:TNKS; NbExp=3; IntAct=EBI-745632, EBI-1105254;
CC       Q9H2K2:TNKS2; NbExp=4; IntAct=EBI-745632, EBI-4398527;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cytoplasm, perinuclear
CC       region. Note=Mainly cytoplasmic localization, but interaction with
CC       NOTCH1 results in nuclear localization and interaction with ABPA3
CC       results in perinuclear localization in macrophages.
CC   -!- MASS SPECTROMETRY: Mass=40566; Method=Electrospray; Range=1-349;
CC       Evidence={ECO:0000269|PubMed:15239670};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF395830; AAL27308.1; -; mRNA.
DR   EMBL; AK000622; BAA91291.1; -; mRNA.
DR   EMBL; AL133352; CAH73566.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49817.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49818.1; -; Genomic_DNA.
DR   EMBL; BC007719; AAH07719.1; -; mRNA.
DR   EMBL; AL359615; CAB94885.1; -; mRNA.
DR   CCDS; CCDS7498.1; -.
DR   PIR; T50633; T50633.
DR   RefSeq; NP_060372.2; NM_017902.2.
DR   UniGene; Hs.500788; -.
DR   PDB; 1H2K; X-ray; 2.15 A; A=1-349.
DR   PDB; 1H2L; X-ray; 2.25 A; A=1-349.
DR   PDB; 1H2M; X-ray; 2.50 A; A=1-349.
DR   PDB; 1H2N; X-ray; 2.84 A; A=1-349.
DR   PDB; 1IZ3; X-ray; 2.80 A; A=1-349.
DR   PDB; 1MZE; X-ray; 2.20 A; A=1-349.
DR   PDB; 1MZF; X-ray; 2.40 A; A=1-349.
DR   PDB; 1YCI; X-ray; 2.70 A; A=1-349.
DR   PDB; 2CGN; X-ray; 2.40 A; A=1-349.
DR   PDB; 2CGO; X-ray; 2.30 A; A=1-349.
DR   PDB; 2ILM; X-ray; 2.30 A; A=1-349.
DR   PDB; 2W0X; X-ray; 2.12 A; A=1-349.
DR   PDB; 2WA3; X-ray; 2.50 A; A=1-349.
DR   PDB; 2WA4; X-ray; 2.50 A; A=1-349.
DR   PDB; 2XUM; X-ray; 2.20 A; A=1-349.
DR   PDB; 2Y0I; X-ray; 2.28 A; A=1-349.
DR   PDB; 2YC0; X-ray; 2.15 A; A=1-349.
DR   PDB; 2YDE; X-ray; 2.28 A; A=1-349.
DR   PDB; 3D8C; X-ray; 2.10 A; A=11-349.
DR   PDB; 3KCX; X-ray; 2.60 A; A=15-349.
DR   PDB; 3KCY; X-ray; 2.59 A; A=15-349.
DR   PDB; 3OD4; X-ray; 2.20 A; A=1-349.
DR   PDB; 3P3N; X-ray; 2.40 A; A=1-349.
DR   PDB; 3P3P; X-ray; 2.60 A; A=1-349.
DR   PDB; 4AI8; X-ray; 2.40 A; A=1-349.
DR   PDB; 4B7E; X-ray; 2.50 A; A=1-349.
DR   PDB; 4B7K; X-ray; 2.39 A; A=1-349.
DR   PDB; 4BIO; X-ray; 2.45 A; A=1-349.
DR   PDB; 4JAA; X-ray; 2.39 A; A=1-349.
DR   PDB; 4NR1; X-ray; 2.68 A; A=1-349.
DR   PDB; 4Z1V; X-ray; 2.10 A; A=1-349.
DR   PDB; 4Z2W; X-ray; 2.50 A; A=1-349.
DR   PDB; 5JWP; X-ray; 2.10 A; A=1-349.
DR   PDBsum; 1H2K; -.
DR   PDBsum; 1H2L; -.
DR   PDBsum; 1H2M; -.
DR   PDBsum; 1H2N; -.
DR   PDBsum; 1IZ3; -.
DR   PDBsum; 1MZE; -.
DR   PDBsum; 1MZF; -.
DR   PDBsum; 1YCI; -.
DR   PDBsum; 2CGN; -.
DR   PDBsum; 2CGO; -.
DR   PDBsum; 2ILM; -.
DR   PDBsum; 2W0X; -.
DR   PDBsum; 2WA3; -.
DR   PDBsum; 2WA4; -.
DR   PDBsum; 2XUM; -.
DR   PDBsum; 2Y0I; -.
DR   PDBsum; 2YC0; -.
DR   PDBsum; 2YDE; -.
DR   PDBsum; 3D8C; -.
DR   PDBsum; 3KCX; -.
DR   PDBsum; 3KCY; -.
DR   PDBsum; 3OD4; -.
DR   PDBsum; 3P3N; -.
DR   PDBsum; 3P3P; -.
DR   PDBsum; 4AI8; -.
DR   PDBsum; 4B7E; -.
DR   PDBsum; 4B7K; -.
DR   PDBsum; 4BIO; -.
DR   PDBsum; 4JAA; -.
DR   PDBsum; 4NR1; -.
DR   PDBsum; 4Z1V; -.
DR   PDBsum; 4Z2W; -.
DR   PDBsum; 5JWP; -.
DR   ProteinModelPortal; Q9NWT6; -.
DR   SMR; Q9NWT6; -.
DR   BioGrid; 120794; 70.
DR   DIP; DIP-35527N; -.
DR   IntAct; Q9NWT6; 135.
DR   MINT; MINT-1465958; -.
DR   STRING; 9606.ENSP00000299163; -.
DR   BindingDB; Q9NWT6; -.
DR   ChEMBL; CHEMBL5909; -.
DR   DrugBank; DB01694; D-tartaric acid.
DR   DrugBank; DB08263; N-(carboxycarbonyl)-D-phenylalanine.
DR   iPTMnet; Q9NWT6; -.
DR   PhosphoSitePlus; Q9NWT6; -.
DR   BioMuta; HIF1AN; -.
DR   DMDM; 32129605; -.
DR   EPD; Q9NWT6; -.
DR   MaxQB; Q9NWT6; -.
DR   PaxDb; Q9NWT6; -.
DR   PeptideAtlas; Q9NWT6; -.
DR   PRIDE; Q9NWT6; -.
DR   DNASU; 55662; -.
DR   Ensembl; ENST00000299163; ENSP00000299163; ENSG00000166135.
DR   GeneID; 55662; -.
DR   KEGG; hsa:55662; -.
DR   UCSC; uc001krj.5; human.
DR   CTD; 55662; -.
DR   DisGeNET; 55662; -.
DR   GeneCards; HIF1AN; -.
DR   HGNC; HGNC:17113; HIF1AN.
DR   HPA; CAB069903; -.
DR   HPA; HPA048742; -.
DR   HPA; HPA065302; -.
DR   MIM; 606615; gene.
DR   neXtProt; NX_Q9NWT6; -.
DR   OpenTargets; ENSG00000166135; -.
DR   PharmGKB; PA29284; -.
DR   eggNOG; KOG2132; Eukaryota.
DR   eggNOG; ENOG410XQDR; LUCA.
DR   GeneTree; ENSGT00530000062914; -.
DR   HOGENOM; HOG000008146; -.
DR   HOVERGEN; HBG051903; -.
DR   InParanoid; Q9NWT6; -.
DR   KO; K18055; -.
DR   OMA; MIKGRYD; -.
DR   OrthoDB; EOG091G0C8E; -.
DR   PhylomeDB; Q9NWT6; -.
DR   TreeFam; TF329609; -.
DR   BioCyc; MetaCyc:HS15407-MONOMER; -.
DR   BRENDA; 1.14.11.16; 2681.
DR   Reactome; R-HSA-1234162; Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha.
DR   SIGNOR; Q9NWT6; -.
DR   ChiTaRS; HIF1AN; human.
DR   EvolutionaryTrace; Q9NWT6; -.
DR   GeneWiki; HIF1AN; -.
DR   GenomeRNAi; 55662; -.
DR   PRO; PR:Q9NWT6; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000166135; -.
DR   CleanEx; HS_HIF1AN; -.
DR   ExpressionAtlas; Q9NWT6; baseline and differential.
DR   Genevisible; Q9NWT6; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0071532; F:ankyrin repeat binding; IPI:UniProtKB.
DR   GO; GO:0031406; F:carboxylic acid binding; IDA:UniProtKB.
DR   GO; GO:0048037; F:cofactor binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IDA:UniProtKB.
DR   GO; GO:0051059; F:NF-kappaB binding; IPI:UniProtKB.
DR   GO; GO:0005112; F:Notch binding; IPI:UniProtKB.
DR   GO; GO:0016706; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors; EXP:Reactome.
DR   GO; GO:0019826; F:oxygen sensor activity; NAS:UniProtKB.
DR   GO; GO:0036140; F:peptidyl-asparagine 3-dioxygenase activity; IDA:UniProtKB.
DR   GO; GO:0036139; F:peptidyl-histidine dioxygenase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0045746; P:negative regulation of Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0061428; P:negative regulation of transcription from RNA polymerase II promoter in response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:0042265; P:peptidyl-asparagine hydroxylation; IDA:UniProtKB.
DR   GO; GO:0042264; P:peptidyl-aspartic acid hydroxylation; IDA:UniProtKB.
DR   GO; GO:0036138; P:peptidyl-histidine hydroxylation; IDA:UniProtKB.
DR   GO; GO:0045663; P:positive regulation of myoblast differentiation; IDA:UniProtKB.
DR   GO; GO:2001214; P:positive regulation of vasculogenesis; NAS:UniProtKB.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.287.1010; -; 1.
DR   InterPro; IPR027445; FIH-1.
DR   InterPro; IPR027452; FIH-1_domII.
DR   InterPro; IPR003347; JmjC_dom.
DR   PANTHER; PTHR12461:SF72; PTHR12461:SF72; 1.
DR   SMART; SM00558; JmjC; 1.
DR   PROSITE; PS51184; JMJC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm; Dioxygenase;
KW   Iron; Metal-binding; Nucleus; Oxidoreductase; Polymorphism;
KW   Reference proteome; Transcription; Transcription regulation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    349       Hypoxia-inducible factor 1-alpha
FT                                inhibitor.
FT                                /FTId=PRO_0000083974.
FT   DOMAIN      142    312       JmjC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00538}.
FT   REGION        2    125       Interaction with VHL.
FT                                {ECO:0000269|PubMed:11641274}.
FT   REGION      181    183       Substrate binding.
FT                                {ECO:0000269|PubMed:21177872}.
FT   REGION      201    203       Substrate binding.
FT                                {ECO:0000269|PubMed:21177872}.
FT   REGION      238    239       Substrate binding.
FT                                {ECO:0000269|PubMed:21177872}.
FT   METAL       199    199       Iron; via tele nitrogen; catalytic.
FT                                {ECO:0000269|PubMed:12432100,
FT                                ECO:0000269|PubMed:12446723,
FT                                ECO:0000269|PubMed:15913349,
FT                                ECO:0000269|PubMed:17135241,
FT                                ECO:0000269|PubMed:20396966,
FT                                ECO:0000269|PubMed:20822901,
FT                                ECO:0000269|PubMed:21251231,
FT                                ECO:0000269|PubMed:21460794}.
FT   METAL       201    201       Iron; catalytic.
FT                                {ECO:0000269|PubMed:12432100,
FT                                ECO:0000269|PubMed:12446723,
FT                                ECO:0000269|PubMed:15913349,
FT                                ECO:0000269|PubMed:17135241,
FT                                ECO:0000269|PubMed:20396966,
FT                                ECO:0000269|PubMed:20822901,
FT                                ECO:0000269|PubMed:21251231,
FT                                ECO:0000269|PubMed:21460794}.
FT   METAL       279    279       Iron; via tele nitrogen; catalytic.
FT                                {ECO:0000269|PubMed:12432100,
FT                                ECO:0000269|PubMed:12446723,
FT                                ECO:0000269|PubMed:15913349,
FT                                ECO:0000269|PubMed:17135241,
FT                                ECO:0000269|PubMed:20396966,
FT                                ECO:0000269|PubMed:20822901,
FT                                ECO:0000269|PubMed:21251231,
FT                                ECO:0000269|PubMed:21460794}.
FT   BINDING     145    145       2-oxoglutarate.
FT                                {ECO:0000269|PubMed:12432100,
FT                                ECO:0000269|PubMed:12446723,
FT                                ECO:0000269|PubMed:21251231}.
FT   BINDING     152    152       Substrate. {ECO:0000269|PubMed:21177872}.
FT   BINDING     196    196       2-oxoglutarate.
FT                                {ECO:0000269|PubMed:12432100,
FT                                ECO:0000269|PubMed:12446723,
FT                                ECO:0000269|PubMed:21251231}.
FT   BINDING     205    205       2-oxoglutarate.
FT                                {ECO:0000269|PubMed:12432100,
FT                                ECO:0000269|PubMed:12446723,
FT                                ECO:0000269|PubMed:21251231}.
FT   BINDING     214    214       2-oxoglutarate.
FT                                {ECO:0000269|PubMed:12432100,
FT                                ECO:0000269|PubMed:12446723,
FT                                ECO:0000269|PubMed:21251231}.
FT   BINDING     294    294       2-oxoglutarate.
FT                                {ECO:0000269|PubMed:12432100,
FT                                ECO:0000269|PubMed:12446723,
FT                                ECO:0000269|PubMed:21251231}.
FT   BINDING     300    300       Substrate; via amide nitrogen.
FT                                {ECO:0000269|PubMed:21177872}.
FT   BINDING     321    321       Substrate. {ECO:0000269|PubMed:21177872}.
FT   SITE        340    340       Important for dimer formation.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   VARIANT      41     41       P -> A (in dbSNP:rs2295778).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_051028.
FT   MUTAGEN     199    199       H->A: Prevents suppression of HIF CAD
FT                                activity. Strongly stimulates 2-
FT                                oxoglutarate turnover. No stimulation of
FT                                2-oxoglutarate turnover; when associated
FT                                with R-340.
FT                                {ECO:0000269|PubMed:12080085}.
FT   MUTAGEN     201    201       D->A: Prevents suppression of HIF CAD
FT                                activity. {ECO:0000269|PubMed:12080085,
FT                                ECO:0000269|PubMed:18611856,
FT                                ECO:0000269|PubMed:21177872}.
FT   MUTAGEN     201    201       D->E: Loss of HIF1A Asn hydroxylation
FT                                activity. Slightly stimulates 2-
FT                                oxoglutarate turnover.
FT                                {ECO:0000269|PubMed:12080085,
FT                                ECO:0000269|PubMed:18611856,
FT                                ECO:0000269|PubMed:21177872}.
FT   MUTAGEN     201    201       D->G: No impact on HIF1A Asn
FT                                hydroxylation activity. Loss of Asp
FT                                hydroxylation ability. Strongly
FT                                stimulates 2-oxoglutarate turnover. Loss
FT                                of HIF1A Asn hydroxylation activity and
FT                                slight stimulation of 2-oxoglutarate
FT                                turnover; when associated with R-296.
FT                                {ECO:0000269|PubMed:12080085,
FT                                ECO:0000269|PubMed:18611856,
FT                                ECO:0000269|PubMed:21177872}.
FT   MUTAGEN     239    239       Q->H: No effect on Asp hydroxylation
FT                                ability. {ECO:0000269|PubMed:21177872}.
FT   MUTAGEN     296    296       W->R: Loss of HIF1A Asn hydroxylation
FT                                activity and slight stimulation of 2-
FT                                oxoglutarate turnover; when associated
FT                                with G-201.
FT                                {ECO:0000269|PubMed:18611856}.
FT   MUTAGEN     340    340       L->R: Impairs dimer formation, leading to
FT                                loss of HIF1A Asn hydroxylation activity.
FT                                No stimulation of 2-oxoglutarate
FT                                turnover; when associated with A-201.
FT                                {ECO:0000269|PubMed:15239670,
FT                                ECO:0000269|PubMed:18611856}.
FT   MUTAGEN     344    344       I->R: No effect on dimer formation and
FT                                HIF1A Asn hydroxylation activity.
FT                                {ECO:0000269|PubMed:15239670}.
FT   CONFLICT     10     10       A -> T (in Ref. 2; BAA91291).
FT                                {ECO:0000305}.
FT   CONFLICT     28     28       D -> H (in Ref. 2; BAA91291).
FT                                {ECO:0000305}.
FT   CONFLICT    156    156       R -> G (in Ref. 2; BAA91291).
FT                                {ECO:0000305}.
FT   HELIX         2      9       {ECO:0000244|PDB:2YC0}.
FT   TURN         20     22       {ECO:0000244|PDB:3D8C}.
FT   STRAND       24     26       {ECO:0000244|PDB:3OD4}.
FT   HELIX        29     31       {ECO:0000244|PDB:3D8C}.
FT   STRAND       39     41       {ECO:0000244|PDB:3D8C}.
FT   HELIX        50     57       {ECO:0000244|PDB:3D8C}.
FT   STRAND       62     65       {ECO:0000244|PDB:3D8C}.
FT   HELIX        71     75       {ECO:0000244|PDB:3D8C}.
FT   HELIX        78     84       {ECO:0000244|PDB:3D8C}.
FT   STRAND       85     88       {ECO:0000244|PDB:3P3P}.
FT   STRAND       90     99       {ECO:0000244|PDB:3D8C}.
FT   HELIX       105    107       {ECO:0000244|PDB:3D8C}.
FT   TURN        108    110       {ECO:0000244|PDB:2YC0}.
FT   STRAND      111    113       {ECO:0000244|PDB:3KCY}.
FT   STRAND      117    123       {ECO:0000244|PDB:3D8C}.
FT   HELIX       125    138       {ECO:0000244|PDB:3D8C}.
FT   STRAND      143    149       {ECO:0000244|PDB:3D8C}.
FT   STRAND      151    154       {ECO:0000244|PDB:1MZE}.
FT   HELIX       156    163       {ECO:0000244|PDB:3D8C}.
FT   HELIX       167    176       {ECO:0000244|PDB:3D8C}.
FT   STRAND      182    184       {ECO:0000244|PDB:3D8C}.
FT   STRAND      186    190       {ECO:0000244|PDB:3D8C}.
FT   STRAND      195    199       {ECO:0000244|PDB:3D8C}.
FT   STRAND      202    212       {ECO:0000244|PDB:3D8C}.
FT   STRAND      214    219       {ECO:0000244|PDB:3D8C}.
FT   HELIX       221    223       {ECO:0000244|PDB:3D8C}.
FT   HELIX       224    227       {ECO:0000244|PDB:3D8C}.
FT   TURN        235    238       {ECO:0000244|PDB:4Z1V}.
FT   STRAND      239    242       {ECO:0000244|PDB:4Z1V}.
FT   STRAND      244    246       {ECO:0000244|PDB:4Z1V}.
FT   TURN        249    251       {ECO:0000244|PDB:3D8C}.
FT   HELIX       253    257       {ECO:0000244|PDB:3D8C}.
FT   STRAND      260    265       {ECO:0000244|PDB:3D8C}.
FT   STRAND      270    273       {ECO:0000244|PDB:3D8C}.
FT   STRAND      278    283       {ECO:0000244|PDB:3D8C}.
FT   STRAND      290    298       {ECO:0000244|PDB:3D8C}.
FT   HELIX       312    329       {ECO:0000244|PDB:3D8C}.
FT   STRAND      330    332       {ECO:0000244|PDB:2WA3}.
FT   HELIX       333    335       {ECO:0000244|PDB:3D8C}.
FT   HELIX       336    344       {ECO:0000244|PDB:3D8C}.
FT   TURN        345    347       {ECO:0000244|PDB:3D8C}.
SQ   SEQUENCE   349 AA;  40285 MW;  96A033BA7B3BD8C7 CRC64;
     MAATAAEAVA SGSGEPREEA GALGPAWDES QLRSYSFPTR PIPRLSQSDP RAEELIENEE
     PVVLTDTNLV YPALKWDLEY LQENIGNGDF SVYSASTHKF LYYDEKKMAN FQNFKPRSNR
     EEMKFHEFVE KLQDIQQRGG EERLYLQQTL NDTVGRKIVM DFLGFNWNWI NKQQGKRGWG
     QLTSNLLLIG MEGNVTPAHY DEQQNFFAQI KGYKRCILFP PDQFECLYPY PVHHPCDRQS
     QVDFDNPDYE RFPNFQNVVG YETVVGPGDV LYIPMYWWHH IESLLNGGIT ITVNFWYKGA
     PTPKRIEYPL KAHQKVAIMR NIEKMLGEAL GNPQEVGPLL NTMIKGRYN
//
